Methods and compositions relating to mesenchymal stem cell exosomes

Abstract

The invention provides compositions comprising mesenchymal stem cell (MSC) derived exosomes, and methods of their use in subjects having certain lung diseases including inflammatory lung disease.

What is claimed is: 
     
         1 .- 58 . (canceled) 
     
     
         59 . A pharmaceutical composition comprising an effective amount of isolated human mesenchymal stem cell (MSC) exosomes for use in a subject having or at risk of developing a lung disease. 
     
     
         60 . The pharmaceutical composition of  claim 59 , wherein the isolated human MSC exosomes are isolated from bone marrow or human umbilical cord blood 
     
     
         61 . The pharmaceutical composition of  claim 59 , wherein the pharmaceutical composition further comprises a pulmonary surfactant. 
     
     
         62 . The pharmaceutical composition of  claim 59 , wherein the subject is a human subject. 
     
     
         63 . The pharmaceutical composition of  claim 62 , wherein the human subject is less than 4 weeks of age. 
     
     
         64 . The pharmaceutical composition of  claim 62 , wherein the human subject is between 3-18 years of age. 
     
     
         65 . The pharmaceutical composition of  claim 62 , wherein the human subject was born prematurely. 
     
     
         66 . The pharmaceutical composition of  claim 65 , wherein the human subject was born less than 37 weeks of gestation. 
     
     
         67 . The pharmaceutical composition of  claim 62 , wherein the human subject has been administered oxygen or has been on a ventilator. 
     
     
         68 . The pharmaceutical composition of  claim 59 , wherein lung disease is inflammatory lung disease, lung vascular disease, or acute lung injury. 
     
     
         69 . The pharmaceutical composition of  claim 59 , wherein the lung disease is pulmonary hypertension, asthma, bronchopulmonary dysplasia (BPD), allergy, or idiopathic pulmonary fibrosis. 
     
     
         70 . The pharmaceutical composition of  claim 69 , wherein the lung disease is BPD. 
     
     
         71 . The pharmaceutical composition of  claim 70 , wherein the BPD is inflammatory. 
     
     
         72 . The pharmaceutical composition of  claim 70 , wherein the BPD is non-inflammatory. 
     
     
         73 . The pharmaceutical composition of  claim 68 , wherein the acute lung injury is associated with sepsis or is ventilator-induced acute respiratory distress syndrome (ARDS). 
     
     
         74 . The pharmaceutical composition of  claim 69 , wherein the subject has or is likely to develop schistosomiasis. 
     
     
         75 . The pharmaceutical composition of  claim 59 , wherein the pharmaceutical composition is administered within 1 day of birth. 
     
     
         76 . The pharmaceutical composition of  claim 75 , wherein the pharmaceutical composition is administered within 1 hour of birth. 
     
     
         77 . The pharmaceutical composition of  claim 59 , wherein pharmaceutical composition is administered intravenously or to lungs or trachea of the subject. 
     
     
         78 . The pharmaceutical composition of  claim 59 , wherein the subject is not receiving a cell or organ transplantation.